Funder
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
European Research Council
National Institute of Allergy and Infectious Diseases
Medical Education Partnership Initiative
Fogarty International Center
Vlaamse Interuniversitaire Raad
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. World Health Organization. WHO endorses new rapid tuberculosis test. 2010. Available from:
http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/
. Accessed on 15/12/2014.
2. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system.; 2011. Available from:
http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf
. Accessed on 31–01-2012.
3. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva: World Health Organization; 2013. Available from:
http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335_eng.pdf
. Accessed on 15/12/2014.
4. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516–25.
5. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.